Seretide (salmeterol/fluticasone propionate) logo
Seretide Evohaler inhalers 50/25 125/25 250/25 3 doses for asthma

Seretide Evohaler - a combination ICS/LABA treatment for asthma

Now over £5 cheaper than Fostair at medium dose1,2

Seretide Evohaler asthma price over £5 cheaper compared to Fostair at medium dose

Has this information made a positive or negative impact on your perception of Seretide Evohaler?

What is Seretide Evohaler?

Asthma Indication4

Seretide is indicated in the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist


  • patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist


The recommended dose of Seretide Evohaler 50/25, 125/25 or 250/25 is two inhalations, twice daily.

Seretide Evohaler comes in three different doses, allowing flexibility of dosing for your patient with asthma at low, medium and high dose inhaled steroid4

Seretide Evohaler 50/25 is licensed for use in paediatric asthma for patients 4 years and above.4


Low Dose (50/25 two puffs B.D)

Medium Dose (125/25 two puffs B.D)
over £5 cheaper than Fostair 100/6 (two puffs B.D)1,2

High Dose (250/25 two puffs B.D)
same price as Fostair 200/6 (two puffs B.D)2,5

Find out how Seretide could help support your patients who have asthma.

What can Seretide help you achieve for your patients?

Asthma symptom control

Seretide is proven to achieve and maintain guideline-defined asthma control3


Seretide is proven to achieve and maintain guideline-defined asthma control in an RCT3

An estimated

3 out of 4

patients* achieved asthma control and remained controlled after 1 year

*GOAL Study Stratum 2 patients defined as those patients who were on 500 μg or less of beclomethasone propionate daily or equivalent.


Rescue-free days

Patients should not need their rescue inhaler
6 days a week6


Seretide is proven to achieve and maintain guideline-defined asthma control in an RCT3

6 out of 7

rescue free days with Seretide*6

*GOAL Study Stratum 2 patients defined as those patients who were on 500 μg or less of beclomethasone propionate daily or equivalent. The GOAL data has been extrapolated from over one year into one week.


Exacerbation rate reduction

Reduced risk of exacerbations with Seretide7,8


21% reduction*

in the risk of severe exacerbations in patients with at least one exacerbation vs fluticasone propionate (p<0.01)7

*The absolute risk reduction compared with ICS alone is 2% (incidence of 8% with Seretide compared to 10% with ICS alone)

76% reduction

in the risk of 2 or more exacerbations over 1 year vs fluticasone propionate (p<0.01)8

Absolute risk reduction is 13% (4.2% risk of ≥2 exacerbations with Seretide vs 17.4% with ICS alone).


Compare Seretide with Fostair in asthma

Seretide Evohaler is over £5 cheaper than Fostair at medium dose1,2, and is the same price as Fostair at high dose2,5

Seretide Evohaler asthma price comparison with Fostair all doses
DoseSeretide EvohalerFostair
Low50/25 (2 puffs B.D)100/6 (1 puff B.D)
Medium125/25 (2 puffs B.D)100/6 (2 puffs B.D)
High250/25 (2 puffs B.D)200/6 (2 puffs B.D)

Seretide Evohaler 50/25 is licensed for Children 4 years and older. Fostair is not licensed for use in under 18's.

Seretide Evohaler 50/25 has a license for paediatric asthma for patients 4 years and above, and all
strengths are licensed in adolescent asthma4.
Fostair is not recommended for children & adolescents under 18 years9

Seretide Evohaler asthma particle size data

The optimal particle size range for delivery to the lungs is 1-5um. Seretide particles are within this range10

There is no evidence that extrafine particles are associated with additional clinically relevant benefits compared with Seretide11,12
This was observed for a number of efficacy endpoints in an extensive scientific literature review and systematic analysis of RCT data, including:

  • FEV1
  • Morning peak flow
  • Rescue medication use12

Therefore you can be confident that particle size does not need to be a factor when choosing between Seretide and Fostair.

When clinically indicated, maintenance and reliever therapy (MART) can be a viable option for patients. However, are you aware of some of its limitations?

Less than 20% of MART-treated patients achieved control, according to GINA criteria13,14

MART-treated patients are only rescue free 4 days a week and many still use a separate reliever15

1 in 5 MART-treated patients have a severe exacerbation each year15

How to use Seretide Evohaler

Free resources to help you and your patients use Seretide Evohaler

Identify patients using the ACT score pad

The Asthma Control Test

Provides a numerical score that helps healthcare professionals and their patients determine if asthma symptoms are well controlled.

Order now
Ellipta inhalation trainer

Help demonstrate the
Evohaler device to patients

This Placebo Demonstration Device helps healthcare professionals show patients how to use the Evohaler device correctly.

Order now
Ellipta demonstration device

Teach patients to use the
Evohaler device

How to Use Patient Leaflet Pad to support patients to correctly use their Evohaler on its own and with a Volumatic Spacer.

Order now

Get started with Seretide Evohaler


  1. MIMS; Fostair 100/6 list price per pack for the treatment of asthma (accessed Oct 2020)
  2. BTS/SIGN Guideline for the Management of Asthma. Table 12 (comparison of medium doses) (accessed Oct 2020)
  3. Bateman ED et al. Am J Respir Crit Care MED 2004; 170:836-844
  4. Seretide Evohaler SPC (accessed Oct 2020)
  5. MIMS; Fostair 200/6 list price per pack for the treatment of asthma (accessed Oct 2020)
  6. Woodcock AA et al. Prim Care Respir J 2007; page 159 Table 3
  7. Stempel DA et al. N Engl J Med 2016; 374:1822-30
  8. Lundbäck B et al. Respir Med 2009; 103:348–355
  9. Fostair SPC (accessed Oct 2020)
  10. Scichilone N, et al. J Asthma Allergy 2013;6:11–21.
  11. Papi A; Allergy; 2007;62;1182-1188
  12. El Baou et al. BMC Pulmonary Medicine 2017;17:31
  13. Bateman ED, et al. J Allergy Clin Immunol 2010;125(3):600–608.
  14. 2019 GINA Report, Global Strategy for Asthma Management and Prevention. Available from: Accessed October 2019.
  15. Chapman KR, et al. Thorax 2010;65(8):747–752.

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Seretide is a registered trademark of the GlaxoSmithKline group of companies

PM-GB-FPS-WCNT-200001 (2.0) October 2020